ACB · Aurora Cannabis Inc · Documents

Aurora Cannabis Inc. agreed to sell all outstanding shares to Organigram for C$7.80 per share, valuing the company at approximately C$561 million on a fully diluted basis and representing a 93% premium; completion is expected in January 2027.

Aurora Cannabis will discuss second quarter 2027 financial results on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time and 6:00 a.m. Mountain Time. Miguel Martin and Simona King will host the call.

The Alberta Securities Commission dismissed Curaleaf’s application to halt Aurora’s ATM program, which Aurora said complies with securities laws. Aurora last used the ATM on August 18, 2026 and unanimously urged shareholders to reject Curaleaf’s revised hostile bid.

Aurora Cannabis Inc. recommends shareholders reject Curaleaf Holdings, Inc.’s revised hostile bid, take no action before December 4, 2026, and await its Special Committee’s evaluation of strategic alternatives.

Aurora Cannabis Inc. completed expansion of its Leuna, Germany EU-GMP facility, renamed Aurora Horizon, increasing cultivation capacity and more than doubling expected annual flower output; newly built areas received an expanded EU-GMP license.

Aurora Cannabis Inc urged shareholders to take no action on Curaleaf’s revised hostile bid, which offers US$5.00 per share, while its Special Committee reviews it; shareholders have until at least December 4, 2026 to consider their options.

Aurora Cannabis Inc advised shareholders to take no action pending its Special Committee’s review because Curaleaf has not filed a formal revised hostile bid; shareholders have until December 4, 2026, with a Board recommendation expected within 15 days.

Aurora Cannabis Inc. asked the Alberta Securities Commission to require Curaleaf to correct hostile bid disclosure deficiencies including pro forma financials and the required 105-day deposit period. The Board unanimously recommends shareholders reject take no action and not tender shares.